My airport driver needs my flight number. Who needs the rest of the email?
An airport pickup shows how much personal data an AI booking service really needs, and what to ask before sharing a family itinerary.


A JOURNAL OF PERSPECTIVE
Progress gives us possibilities.
Perspective helps us choose.
Notes on health, money and the future—exploring what is changing, what we may have overlooked, and what it could mean for our lives.
TURN THE PERSPECTIVE
If we can detect more, what should we do differently?Fresh questions. Considered perspectives.
An airport pickup shows how much personal data an AI booking service really needs, and what to ask before sharing a family itinerary.
The firm is licensed. How do you check whether the person who sent the offer represents it?
What melanoma patients and investors can each learn from the same trial.
A pharmacy reading, a kaya toast excuse and one question to ask before you leave.
Three siblings split Mum’s clinic bill. What about the half-day’s pay her daughter gave up to take her?
A parent can keep the value of an investment private and still tell the family which broker to call.
Two parents can have the same EPF balance and very different room to give. What i-Legasi changes for EPF, for families and for your own retirement.
The reasoning behind Solve Everything, two real research examples, and what I take from a hopeful—but uncertain—medical future.
A fake interview was one entry point. My takeaway: security should allow for human mistakes and limit how far one breach can spread.
Humanoid robots invite us to imagine a future with more independence, better support—and perhaps someone else doing the washing-up.
Manufactured organs could expand our options. What separates a scientific breakthrough from a treatment a particular family can actually access?
Google Cloud revenue doubled, yet Alphabet shares fell. A closer look at growth, expectations and the cash needed to build AI’s future.
ER-100 brings new hope for restoring function. How should we think about longer lives when healthy years and care needs remain uncertain?
MediAsas invites a better comparison: what costs would a plan carry, what would our household retain, and could we sustain both through a difficult year?
A legacy needs a workable handover as well as valuable assets. Who could access cash, with what authority, and when?
AlphaGenome Atlas offers more promising research clues. My view on separating faster discovery from better outcomes—and asking who will be ready to benefit.
Earlier cancer detection offers a hopeful possibility: more time to understand, prepare and explore our options. What would help us make that time count?
A NOTE FROM THE EDITOR
“I’m interested in a brighter future.
And the questions that help us prepare for it.”
Hope and preparation belong in the same conversation. This journal makes room for both.
A little more about Risk Steward ↗Health & Longevity
What if growing older did not have to mean steadily losing the abilities we value?
That is the possibility that draws me to epigenetic reprogramming: research exploring whether some older or damaged cells can recover more youthful function.

ER-100 is an experimental gene therapy from Life Biosciences, a company co-founded by Harvard geneticist David Sinclair. It uses controlled activity of three factors—OCT4, SOX2 and KLF4—to try to reset aspects of how cells use their genetic instructions. The aim is partial reprogramming, rather than turning mature cells completely back into stem cells. [1]
An important foundation was a 2020 study from Sinclair and colleagues, which reported improved vision and regeneration in mouse experiments. Those findings were in mice; they did not establish that people could live longer. [2]
Now, ER-100 is being studied in people with optic nerve conditions, including glaucoma. On 8 October 2026, Life Biosciences reported that the first three glaucoma participants tolerated treatment through 56 days, with preliminary visual-field improvements in two. [3]
These encouraging findings were company-reported interim observations from a tiny, open-label safety study without a randomized control group. They do not prove that aging has been reversed in people, that blindness has been cured, or that lifespan has increased. Sinclair’s role in the company also matters when interpreting its announcements. [3] [4]
Seeing clearly. Staying active. More time with people we love.
More birthdays would be welcome. More healthy birthdays would be even better.
This connects with longevity escape velocity (LEV): the hypothetical point at which successive medical advances extend remaining life expectancy faster than time passes. It is an idea about sustained future progress, not an achievement demonstrated by ER-100. [5]
We do not know whether—or when—we will reach it. I see two separate uncertainties: how long we might live, and how much of that time we could remain independent. A treatment that improves one aspect of health would not settle either question for our whole lives.
Rather than choosing a single prediction, I would test two possibilities: more healthy years, and more years needing support. Would our income, care arrangements and family responsibilities remain workable in each? That lets us welcome progress without making our plans depend on a breakthrough arriving on time.
If science gives us more good years, I would rather the retirement fund did not retire before we do.
Research checked: 1 November 2026. General education and personal commentary, not medical advice. ER-100 remains investigational; permission to conduct a trial is not approval for routine treatment.
[1] Life Biosciences: ER-100 trial clearance and background
[3] Life Biosciences: Interim Phase 1 observations, 8 October 2026
A QUESTION TO CARRY FORWARD
Original article ↗